"Irradiated B7-1 Transduced Primary Acute Myelogenous Leukemia (AML) Cells Can Be Used As Therapeutic Vaccines in Murine AML."

According to the authors' abstract of an article published in Blood, "Recent studies have shown that tumor cells genetically modified by transduction of B7-1, a natural ligand for the T-cell costimulatory molecules CD28 and CTLA-4, are rejected in syngeneic hosts. In these reports, transformed cell lines and drug-selected cells have been used for vaccinations. To determine the effectiveness of B7-1-transduced primary acute myelogenous leukemia (AML) cells on the induction of antitumor immunity, we have studied a murine AML model in which primary AML cells were retrovirally transduced with the murine B7-1 cDNA. A defective retroviral producer clone expressing B7-1 and secreting a high...

Want to see the full article?

• Purchase this article for only $3.00